Annual report
4551.TEDINET S100QGWM
Period2022-01-01 → 2022-12-31
Filed2023-03-28
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 89
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥48.9bn | 2022-01-01 → 2022-12-31 | Standalone | Net sales |
| Revenue | ¥47.0bn | 2021-01-01 → 2021-12-31 | Standalone | Net sales |
| Revenue | ¥41.7bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥43.0bn | 2019-01-01 → 2019-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥62.6bn | 2018-01-01 → 2018-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥5.5bn | 2022-01-01 → 2022-12-31 | Standalone | Operating income |
| Operating income | ¥4.7bn | 2021-01-01 → 2021-12-31 | Standalone | Operating income |
| Ordinary income | ¥5.5bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.8bn | 2021-01-01 → 2021-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥5.0bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.7bn | 2019-01-01 → 2019-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.1bn | 2018-01-01 → 2018-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.7bn | 2022-01-01 → 2022-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥4.8bn | 2021-01-01 → 2021-12-31 | Standalone | Income before income taxes |
| Net income | ¥3.9bn | 2022-01-01 → 2022-12-31 | Standalone | Profit loss |
| Net income | ¥3.4bn | 2021-01-01 → 2021-12-31 | Standalone | Profit loss |
| Net income | ¥3.5bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥27.4bn | 2019-01-01 → 2019-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.2bn | 2018-01-01 → 2018-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥133.7bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥130.8bn | at 2021-12-31 | Standalone | Assets |
| Total assets | ¥126.0bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥139.9bn | at 2019-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥103.3bn | at 2018-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥14.5bn | at 2022-12-31 | Standalone | Liabilities |
| Total liabilities | ¥13.8bn | at 2021-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥119.2bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥117.0bn | at 2021-12-31 | Standalone | Net assets |
| Net assets / equity | ¥115.1bn | at 2020-12-31d | Standalone | Net assets |
| Net assets / equity | ¥113.1bn | at 2019-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥87.1bn | at 2018-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥9.2bn | at 2022-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.0bn | at 2021-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥45.4bn | at 2022-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥58.4bn | at 2021-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥61.6bn | at 2020-12-31d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥58.8bn | at 2019-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥15.7bn | at 2018-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.4bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥156m | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥3.4bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥42.5bn | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.3bn | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥13.7bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.5bn | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥7.6bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥2.1bn | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥27.1bn | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥1.7bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.5bn | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.4bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.4bn | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.4bn | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥140.39 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥120.13 | 2021-01-01 → 2021-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥124.47 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥974.98 | 2019-01-01 → 2019-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.51 | 2018-01-01 → 2018-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥124.46 | 2020-01-01 → 2020-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥100 | 2022-01-01 → 2022-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2021-01-01 → 2021-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2020-01-01 → 2020-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2019-01-01 → 2019-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2018-01-01 → 2018-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥4,243.08 | at 2022-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,165.38 | at 2021-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,097.55 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,029.3 | at 2019-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,103.28 | at 2018-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 89.2% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2021-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.3% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.8% | at 2019-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.3% | at 2018-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.3% | 2022-01-01 → 2022-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.9% | 2021-01-01 → 2021-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.1% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 27.3% | 2019-01-01 → 2019-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.3% | 2018-01-01 → 2018-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 28,800,000 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 28,800,000 | at 2021-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 28,800,000 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 28,800,000 | at 2019-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 28,800,000 | at 2018-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 563 | at 2022-12-31 | Standalone | Number of employees |
| Employees | 560 | at 2021-12-31 | Standalone | Number of employees |
| Employees | 568 | at 2020-12-31d | Standalone | Number of employees |
| Employees | 660 | at 2019-12-31d | Standalone | Number of employees |
| Employees | 1,049 | at 2018-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 1
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Businessreportable segment | employees | at 2022-12-31 | 563 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 987
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration_NonConsolidatedMember | -156000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 2420000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior4YearDuration_NonConsolidatedMember | -27068000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 2099000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 7625000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration_NonConsolidatedMember | -1498000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYearDuration_NonConsolidatedMember | -13676000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior4YearDuration_NonConsolidatedMember | -1432000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior3YearDuration_NonConsolidatedMember | -1433000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior2YearDuration_NonConsolidatedMember | -1425000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration_NonConsolidatedMember | -1546000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYearDuration_NonConsolidatedMember | -1698000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 15654000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 58819000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 61576000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 58374000000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 45420000000 | JPY |
| Number of employees | Prior4YearInstant_NonConsolidatedMember | 1049 | |
| Number of employees | Prior3YearInstant_NonConsolidatedMember | 660 | |
| Number of employees | Prior2YearInstant_NonConsolidatedMember | 568 | |
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 560 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 563 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 148 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 116 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 51 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 25 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 34 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.820 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.043 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 1.112 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 1.015 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 1.060 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 0.840 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 0.992 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.066 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.202 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.172 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 563 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 34 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 40.4 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 14.4 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 8224000 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00934-000PharmaceuticalBusinessReportableSegmentMember | 563 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00934-000PharmaceuticalBusinessReportableSegmentMember | 34 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 563 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 34 | |
| Research and development expenses research and development activities | CurrentYearDuration | 1661000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 662000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 28800000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 28800000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |